Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy
Lei Zhou, … , Haitao Wen, Zihai Li
Lei Zhou, … , Haitao Wen, Zihai Li
Published May 24, 2024
Citation Information: J Clin Invest. 2024;134(14):e180080. https://doi.org/10.1172/JCI180080.
View: Text | PDF
Research Article Immunology Oncology

Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy

  • Text
  • PDF
Abstract

Intratumoral Tregs are key mediators of cancer immunotherapy resistance, including anti–programmed cell death (ligand) 1 [anti–PD-(L)1] immune checkpoint blockade (ICB). The mechanisms driving Treg infiltration into the tumor microenvironment (TME) and the consequence on CD8+ T cell exhaustion remain elusive. Here, we report that heat shock protein gp96 (also known as GRP94) was indispensable for Treg tumor infiltration, primarily through the roles of gp96 in chaperoning integrins. Among various gp96-dependent integrins, we found that only LFA-1 (αL integrin), and not αV, CD103 (αE), or β7 integrin, was required for Treg tumor homing. Loss of Treg infiltration into the TME by genetic deletion of gp96/LFA-1 potently induced rejection of tumors in multiple ICB-resistant murine cancer models in a CD8+ T cell–dependent manner, without loss of self-tolerance. Moreover, gp96 deletion impeded Treg activation primarily by suppressing IL-2/STAT5 signaling, which also contributed to tumor regression. By competing for intratumoral IL-2, Tregs prevented the activation of CD8+ tumor-infiltrating lymphocytes, drove thymocyte selection-associated high mobility group box protein (TOX) induction, and induced bona fide CD8+ T cell exhaustion. By contrast, Treg ablation led to striking CD8+ T cell activation without TOX induction, demonstrating clear uncoupling of the 2 processes. Our study reveals that the gp96/LFA-1 axis plays a fundamental role in Treg biology and suggests that Treg-specific gp96/LFA-1 targeting represents a valuable strategy for cancer immunotherapy without inflicting autoinflammatory conditions.

Authors

Lei Zhou, Maria Velegraki, Yi Wang, J K Mandula, Yuzhou Chang, Weiwei Liu, No-Joon Song, Hyunwoo Kwon, Tong Xiao, Chelsea Bolyard, Feng Hong, Gang Xin, Qin Ma, Mark P. Rubinstein, Haitao Wen, Zihai Li

×

Figure 4

LFA-1 blockade prevents Treg infiltration into the TME.

Options: View larger image (or click on image) Download as PowerPoint
LFA-1 blockade prevents Treg infiltration into the TME.
(A) Experimental...
(A) Experimental scheme illustrates the process of LFA-1 blockade using anti–LFA-1 or IgG2a isotype-matched control Abs in C57BL/6 mice implanted with MC38 tumor cells. Anti–LFA-1 or isotype Abs were administered every 2 days starting from day 4 after MC38 tumor cell implantation on day 0; TIL analysis was conducted on day 9 (n = 7/group) and day 16 (n = 7/group). (B–D) Spectral flow cytometric analysis of CD45+ TILs from day-9 MC38 tumors treated with anti–LFA-1 or isotype Abs. LFA-1 blockade significantly reduced the frequency of cluster 1 (NK cells), cluster 2 (including CD3+CD4+Foxp3– non-Tregs and CD3+CD4+Foxp3+ Tregs), and cluster 12 (CD8+ T cells) (highlighted in blue). As a subset of CD4+ T cells, Tregs expressed high levels of Foxp3 and were located at the bottom of cluster 2. (C) UMAP visualization shows the distribution of the indicated markers. (D) edgeR analysis indicating CD45+ TILs clusters with significant changes to frequency following treatment with anti–LFA-1 (left) versus isotype Abs (right). (E) Representative flow cytometric plots and graph depict the percentages of Foxp3+ Tregs in CD45+ TILs from day-9 MC38 tumors. (F–H) Spectral flow cytometric analysis of CD45+ TILs from day-16 MC38 tumors treated with anti–LFA-1 or isotype Abs. Similar to results in B, cluster 2 (NK cells), cluster 3 (including CD3+CD4+Foxp3– non-Tregs and CD3+CD4+Foxp3+ Tregs), and cluster 4 (CD8+ T cells) exhibited reduced abundance following LFA-1 blockade (highlighted in blue). (F) FoxP3+ Tregs were localized at the bottom of cluster 3. (G) UMAP visualization shows the distribution of the indicated markers. (H) edgeR analysis indicating CD45+ TILs clusters with significant changes to frequency following anti–LFA-1 versus isotype Ab treatment. (I) Representative flow cytometric plots and graph depict the percentages of Foxp3+ Tregs in CD45+ TILs from day-16 MC38 tumors. Results are representative of 3 independent experiments. Data are shown as the mean ± SEM. ****P < 0.0001 (anti–LFA-1 vs. isotype), by 2-tailed Student’s t test for comparisons of different experimental groups (E and I). FC, fold change.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts